SLS · Biotech · Nasdaq · As of 22 Nov 2026
SELLAS Life Sciences Group, Inc. stock: filings, catalysts and timeline
Sign in to follow
AIR Score
Neutral · 58 / 100
AIR confidence
Support behind the full AIR read.
What is this? →Hide
How much data stands behind the whole AIR read — all five perspectives, not just the Discovery Gap. Each perspective reports how complete its inputs are, and these are combined in the same proportions as the AIR Score; a perspective AIR could not score adds nothing, so missing data lowers this figure. It describes the data, not the company.
The Discovery Gap
Very high
Gap confidence
How fully AIR could measure this Gap — separate from the AIR Score's confidence.
What is this? →Hide
How fully AIR could measure both sides of the Discovery Gap: the documented progress (News flow) and market attention (Recognition). It takes the weaker of the two, and reads zero when either side has no measurement. It describes the data, not the company.
Five perspectives
FundamentalsWhat is this?HideNot scored — public float outside AIR's $300M–$20B fundamentals band
How the business is doing on its own reported US-GAAP numbers — growth, margins, cash generation, balance-sheet strength, capital efficiency and dilution — compared with sector peers.
Source: SEC XBRL financial statements.
ValueWhat is this?HidePre-revenue — no valuation basis
How the shares are priced against sector peers, against the company's own recent history, and against a simple cash-flow estimate, using the filing numbers and the current price. AIR shows this as a band, never as a target price.
Source: SEC XBRL financial statements and end-of-day prices.
News flowWhat is this?HideBalanced
What the company has documented recently: material 8-K events (contracts, deals, results, leadership changes) and FDA approvals, weighted by recency and type. A language model's reading of each 8-K helps classify whether it is positive or negative. Filings, not press or social media.
Source: SEC EDGAR 8-K filings and FDA approvals.
MomentumWhat is this?HideStrong
The longer-term market read: the trend in end-of-day prices, strength against the market and the sector, and trading volume over roughly the past three to twelve months. It is shown, never used to rank the Shortlist.
Source: End-of-day prices.
SafetyWhat is this?HideBalanced
The risk side: leverage, liquidity, cash runway, dilution, revenue and margin swings, company size and pre-commercial status, negative 8-K events (including legal and regulatory ones), and share-price drawdown and volatility. Higher means fewer of those risk markers.
Source: SEC XBRL financial statements, SEC EDGAR 8-K filings and end-of-day prices.
Rating words, not raw numbers.
Discovery Gap: Very high (70/100) · Gap confidence 63/100
Discovery gap
Documented progress is running well ahead of market attention.
Low is the most common level — the cut-offs are fixed, and levels can shift as scores refresh.
What is this?Hide
How far documented progress (News flow) runs ahead of market attention. Attention is measured from institutional holdings reported to the SEC, trading volume, price behaviour and how richly the shares are valued — not from social media or analyst ratings.
Source: SEC EDGAR filings (8-K and 13F), FDA approvals and end-of-day prices.
How levels work. The levels use fixed cut-offs, but market attention is ranked against the other ~1,800 companies AIR covers that day (valuation against the same sector). Documented progress counts filings from the past 18 months, newer ones weighing more; attention uses the latest quarter of institutional holdings, the last three to six months of trading, and six to twelve months of price behaviour. Many companies show a Low Gap or none at all — a gap needs filings that read more positively than neutral. A level can change from one day to the next as scores refresh and the other companies move.
This month at a glance
Evidence timeline
What changed — last 90 days
As of 21 Nov 2026The company filed its quarterly report for the period ending September 30, 2026.
Quarterly/annual report · 10-Q filed 12 Nov →
The company reported Q3 2026 cash of $134.7M, Phase 3 REGAL trial 80th event triggering topline results, Phase 2 SLS009 enrollment at 40/80 patients, and Phase 2 relapsed/refractory AML data showing 54-57% ORR.
Results · 8-K filed 12 Nov →
The company completed an underwritten public offering of 11.5M shares at $13.00/share, raising approximately $150M gross proceeds and approximately $161.8M net including option exercise.
Major contract · 8-K filed 20 Nov →
What the company disclosed, not verified by AIR · sources link to the Evidence timeline below.
- Expected
Fri 19 Mar · expected 10-K
Last year filed 19 Mar 2026.
Wed 12 May · expected 10-Q
Last year filed 12 May 2026.
- Filed
Fri 20 Nov · 8-K
8-K · Items 1.01, 8.01 — Material agreement
SELLAS completed an underwritten public offering of 11.5M shares at $13.00/share, raising ~$150M gross proceeds (~$161.8M net including option exercise). Offering closes November 20, 2026.
Recognition: Balanced 56 → Balanced 51Gap High · 40 → Very high · 70Market attention has faded.
Progress is running ahead of attention.
The price trend weakened.
Tue 17 Nov · 8-K
8-K · Item 8.01 — Other events
Recognition: Watch 36 → Balanced 52More of the market is starting to notice.
The price trend strengthened.
Thu 12 Nov · 10-Q
Quarterly report (10-Q), period ending 30 Sep 2026
Recognition: Watch 39 → Watch 32Gap High · 28 → Very high · 45Market attention has faded.
Progress is running ahead of attention.
The price trend weakened.
Thu 12 Nov · 8-K
8-K · Item 2.02 — Results of operations
SELLAS announced Q3 2026 results with $134.7M cash, Phase 3 REGAL trial 80th event triggering topline results expected this month, Phase 2 SLS009 enrollment at 40/80 patients with Q4 data expected, and favorable Phase 2 relapsed/refractory AML data (54-57% ORR).
Recognition: Watch 39 → Watch 32Gap High · 28 → Very high · 45Market attention has faded.
Progress is running ahead of attention.
The price trend weakened.
Tue 11 Aug · 10-Q
Quarterly report (10-Q)
Tue 11 Aug · 8-K
Mon 27 Jul · 8-K
Thu 25 Jun · 8-K
Thu 18 Jun · 8-K
Tue 2 Jun · 8-K
Tue 12 May · 10-Q
Quarterly report (10-Q)
Tue 12 May · 8-K
Thu 19 Mar · 10-K
Annual report (10-K)
Thu 19 Mar · 8-K
Wed 11 Mar · 8-K
Thu 8 Jan · 8-K
Solid dots: a filing AIR classified as material. Grey: routine. Hollow: expected, from last year's dates — not a forecast.
Ask AIR
What would change our view
Research, not tips. No buy/sell recommendations, no price forecasts. Every score is derived from public filings and market data — figures round to whole numbers and refresh each trading day.